{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T22:05:47Z","timestamp":1769637947956,"version":"3.49.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"NIH","award":["R24 DA018055"],"award-info":[{"award-number":["R24 DA018055"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.bcp.2015.09.014","type":"journal-article","created":{"date-parts":[[2015,9,21]],"date-time":"2015-09-21T17:42:34Z","timestamp":1442857354000},"page":"564-572","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"title":["NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid has enhanced chemo-preventive properties compared to aspirin, is gastrointestinal safe with all the classic therapeutic indications"],"prefix":"10.1016","volume":"98","author":[{"given":"Ravinder","family":"Kodela","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitali","family":"Chattopadhyay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4535-1835","authenticated-orcid":false,"given":"Carlos A.","family":"Vel\u00e1zquez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4060-7283","authenticated-orcid":false,"given":"Khosrow","family":"Kashfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2015.09.014_bib0005","first-page":"4399","article-title":"Colorectal cancer risk, chronic illnesses, operations, and medications: case-control results from the Melbourne colorectal cancer study","volume":"48","author":"Kune","year":"1988","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2015.09.014_bib0010","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1056\/NEJMoa021735","article-title":"A randomized trial of aspirin to prevent colorectal adenomas","volume":"348","author":"Baron","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2015.09.014_bib0015","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S0016-5085(03)00887-4","article-title":"Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial","volume":"125","author":"Benamouzig","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bcp.2015.09.014_bib0020","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa021633","article-title":"A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer","volume":"348","author":"Sandler","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2015.09.014_bib0025","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S0140-6736(11)61720-0","article-title":"Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials","volume":"379","author":"Rothwell","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2015.09.014_bib0030","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/S0140-6736(12)60209-8","article-title":"Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials","volume":"379","author":"Rothwell","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2015.09.014_bib0035","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM199906173402407","article-title":"Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs","volume":"340","author":"Wolfe","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2015.09.014_bib0040","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1152\/physrev.00004.2008","article-title":"NSAIDs, and gastric mucosal protection: why doesn\u2019t the stomach digest itself?","volume":"88","author":"Wallace","year":"2008","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.bcp.2015.09.014_bib0045","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1021\/ml300002m","article-title":"NOSH-aspirin: a novel nitric oxide\u2013hydrogen sulfide-releasing hybrid: a new class of anti-inflammatory pharmaceuticals","volume":"3","author":"Kodela","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2015.09.014_bib0050","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1053\/gast.2000.9304","article-title":"Nitric oxide in mucosal defense: a little goes a long way","volume":"119","author":"Wallace","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bcp.2015.09.014_bib0055","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.gtc.2009.03.001","article-title":"Prevention of nonsteroidal anti-inflammatory drug-induced ulcer: looking to the future","volume":"38","author":"Fiorucci","year":"2009","journal-title":"Gastroenterol. Clin. North Am."},{"key":"10.1016\/j.bcp.2015.09.014_bib0060","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.bbrc.2012.02.051","article-title":"NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model","volume":"419","author":"Chattopadhyay","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2015.09.014_bib0065","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1476-5381.1984.tb16447.x","article-title":"The anti-ulcerogenic activity of the unripe plantain banana (Musa species)","volume":"82","author":"Best","year":"1984","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2015.09.014_bib0070","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1124\/jpet.110.171017","article-title":"Comparison between 3-nitrooxyphenyl acetylsalicylate (NO-ASA) and O2-(acetylsalicyloxymethyl)-1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (NONO-ASA) as safe anti-inflammatory, analgesic, antipyretic, antioxidant prodrugs","volume":"335","author":"Chattopadhyay","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2015.09.014_bib0075","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1124\/jpet.112.201970","article-title":"Positional isomers of aspirin are equally potent in inhibiting colon cancer cell growth: differences in mode of cyclooxygenase inhibition","volume":"345","author":"Kodela","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2015.09.014_bib0080","first-page":"502","article-title":"Antiinflammatory, analgesis and antipyretic effects of glaucine in rats and mice","volume":"4","author":"Pinto","year":"1998","journal-title":"Pharm. Pharmacol. Commun."},{"key":"10.1016\/j.bcp.2015.09.014_bib0085","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3181\/00379727-111-27849","article-title":"Carrageenin-induced edema in hind paw of the rat as an assay for antiiflammatory drugs","volume":"111","author":"Winter","year":"1962","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.bcp.2015.09.014_bib0090","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/blood-2002-12-3882","article-title":"Platelet-collagen interaction: is GPVI the central receptor?","volume":"102","author":"Nieswandt","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2015.09.014_bib0095","unstructured":"American-Gastroenterological-Association, 2005. Study shows long-term use of NSAIDs causes severe intestinal damage ScienceDaily, http:\/\/www.sciencedaily.com\/releases\/2005\/01\/50111123706.htm."},{"key":"10.1016\/j.bcp.2015.09.014_bib0100","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s40261-013-0052-6","article-title":"Relative cardiovascular and gastrointestinal safety of non-selective non-steroidal anti-inflammatory drugs versus cyclo-oxygenase-2 inhibitors: implications for clinical practice","volume":"33","author":"Patricio","year":"2013","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.bcp.2015.09.014_bib0105","first-page":"632","article-title":"NSAIDs and kidney","volume":"52","author":"Ejaz","year":"2004","journal-title":"J. Assoc. Physicians India"},{"key":"10.1016\/j.bcp.2015.09.014_bib0110","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1039\/c3md00185g","article-title":"Synthesis and biological activity of NOSH-naproxen (AVT-219) and NOSH-sulindac (AVT-18A) as potent anti-inflammatory agents with chemotherapeutic potential","volume":"4","author":"Kodela","year":"2013","journal-title":"Med. Chem. Commun."},{"issue":"Suppl. 2","key":"10.1016\/j.bcp.2015.09.014_bib0115","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S1590-8658(03)00047-1","article-title":"NO-aspirin: mechanism of action and gastrointestinal safety","volume":"35","author":"Fiorucci","year":"2003","journal-title":"Digest. Liver Dis."},{"key":"10.1016\/j.bcp.2015.09.014_bib0120","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1053\/j.gastro.2006.11.042","article-title":"Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat","volume":"132","author":"Wallace","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bcp.2015.09.014_bib0125","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.redox.2015.08.014","article-title":"Positional isomerism markedly affects the growth inhibition of colon cancer cells by NOSH-aspirin: COX inhibition and modeling","volume":"6","author":"Vannini","year":"2015","journal-title":"Redox Biol."},{"key":"10.1016\/j.bcp.2015.09.014_bib0130","first-page":"229","article-title":"Mechanisms of nonsteroidal anti-inflammatory drug-induced gastrointestinal injury and repair: a window of opportunity for cyclooxygenase-inhibiting nitric oxide donors","volume":"18","author":"Perini","year":"2004","journal-title":"Can. J. Gastroenterol."},{"key":"10.1016\/j.bcp.2015.09.014_bib0135","first-page":"31","article-title":"Anti-inflammatory agents as cancer therapeutics","volume":"57","author":"Kashfi","year":"2009","journal-title":"Adv. Pharmacol. (San Diego, Calif.)"},{"key":"10.1016\/j.bcp.2015.09.014_bib0140","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.bcp.2012.10.019","article-title":"Biology and therapeutic potential of hydrogen sulfide and hydrogen sulfide-releasing chimeras","volume":"85","author":"Kashfi","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2015.09.014_bib0145","first-page":"1","article-title":"NOSH-aspirin (NBS-1120), a dual nitric oxide and hydrogen sulfide-releasing hybrid, reduces inflammatory pain","volume":"3","author":"Fonesca","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.bcp.2015.09.014_bib0150","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jnci\/djn485","article-title":"Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials","volume":"101","author":"Cole","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bcp.2015.09.014_bib0155","article-title":"Why we should not skip aspirin in cardiovascular prevention","volume":"35","author":"Schror","year":"2015","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.bcp.2015.09.014_bib0160","doi-asserted-by":"crossref","first-page":"e0127194","DOI":"10.1371\/journal.pone.0127194","article-title":"Aspirin for primary prevention of cardiovascular disease and cancer. A benefit and harm analysis","volume":"10","author":"Stegeman","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2015.09.014_bib0165","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nrd794","article-title":"Potential cardioprotective actions of no-releasing aspirin","volume":"1","author":"Wallace","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2015.09.014_bib0170","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.clpt.2005.01.011","article-title":"Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake","volume":"77","author":"Huledal","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2015.09.014_bib0175","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejphar.2010.08.039","article-title":"Activity of a new hydrogen sulfide-releasing aspirin (ACS14) on pathological cardiovascular alterations induced by glutathione depletion in rats","volume":"648","author":"Rossoni","year":"2010","journal-title":"Eur. J. Pharmacol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295215006243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295215006243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T12:59:36Z","timestamp":1757768376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295215006243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0006295215006243"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2015.09.014","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid has enhanced chemo-preventive properties compared to aspirin, is gastrointestinal safe with all the classic therapeutic indications","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2015.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}